Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
about
Cord blood graft engineeringA new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on MelanomapiggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.Sleeping beauty system to redirect T-cell specificity for human applications.A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Immunotherapy in acute leukemiaDerivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignanciesThe hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptorCombining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Anti-GD2 Strategy in the Treatment of NeuroblastomaConcise review: umbilical cord blood transplantation: past, present, and futureGenetically engineered T cells for the treatment of cancer.Antibody-based immunotherapy in high-risk neuroblastoma.Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cellsReprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentBayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size.Cellular therapies in acute lymphoblastic leukemiaEx vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche.Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.Umbilical cord-derived stem cells for tissue therapy: current and future uses.Unrelated umbilical cord blood transplantation and immune reconstitution.Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional.Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transImaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.PET imaging of T cells derived from umbilical cord blood.Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunityIL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.Double umbilical cord blood transplant: more than a cell dose?Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.Novel cord blood transplant therapies.Umbilical cord blood immunology: relevance to stem cell transplantation.Advances in umbilical cord blood cell therapy: the present and the future.
P2860
Q26822376-5E7169E3-EA6E-4267-BD1D-0EE2B4F06777Q26849476-93DB1C4D-91F7-472A-BC9C-7D385A2024C3Q27346600-D060C5FC-556B-4007-BC94-0EA99ED2E329Q30496580-A605AAD0-75A9-405D-A569-ECF569C5BAAFQ30535187-9444D305-3748-4715-A6ED-E544C687CB43Q30584839-0ADC15AE-6768-4E60-AF62-F3CA3179DA71Q33633262-563B2ABE-13F8-44A2-8F5B-877BD14DB560Q33731552-C5FD319C-C409-4EAD-B69E-6DC5886C5F95Q33780277-BC5F41FF-593F-4339-A424-85707F290901Q33819935-42FD193B-E120-4DB2-9855-AB1B28CBF29BQ33852140-E654FC7B-F30A-489E-854F-DD337FCFF775Q33862876-6B8C387B-8B3B-4099-B493-8875A74A063EQ34122292-531529BD-552E-47CC-8788-C0727E712E9CQ34243887-6FA94665-6C7B-432D-BEBF-3E52506CC3D6Q34601968-E682A845-FD13-42DD-A242-735296A0C9A3Q34645898-D800F348-A530-4A59-9274-783CA354C638Q34725758-93A0C727-373C-459E-A7C8-8B32281F7725Q34760414-8B062708-B7B6-4C4D-89DB-FC9032BB02A9Q34987908-D451DF46-0291-475C-B135-4416BF77FBFCQ35962978-82E6E03E-67CF-44A0-9368-CB04F9B33469Q35967452-751DCA05-6B4A-4A4F-89FC-B5F61B3D2E92Q36408968-CEC3C317-124B-42C1-8616-B2BD74B43E14Q36552098-967BDDB4-373C-4F19-A7F4-151B3C96AFCCQ36681962-62BD5391-DA2A-4884-A778-3A6F96C5666CQ36713904-C334F7CE-B4D2-48FD-BC3C-6AE0D379396AQ36801106-EE32ED04-D327-4109-A38C-2FD1DFDB6B9BQ36804511-36B20D7F-26F3-445D-9B94-C6E3C155FBF1Q36934304-C1F6C680-40DB-4AD3-B909-0D7F1EF3FC71Q37039243-09F3D1C2-9D30-4E44-A20D-6BD4B37DAFC1Q37339212-8BE46F59-274F-4F0B-8E6B-FA7A29B4C1BBQ37395931-43777A73-E212-495E-A333-627BC7A136E7Q37412238-431CE620-9352-4E63-851A-633064B84381Q37469199-B649CC8C-0BDB-4F73-B222-CC9AEB702A37Q37536195-85FA57E3-3324-4EA1-B36C-6C4540A6F29EQ37724186-0830D3EE-5DEE-407D-A44C-7119AECA3EACQ37751873-8DA5895D-5220-4235-9BC0-C72D1F421C26Q37785538-47353338-4ACE-4830-BE6B-E60933B18A81Q37800641-D37B9BFB-BDC1-4FDA-BB64-65A384A6D32BQ37963798-C1E2207E-30D1-42F1-8FB7-61154E267139Q38734758-5F72C0AD-2F6E-47B1-A251-08C112DA36D3
P2860
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Differentiation of naive cord- ...... tation adoptive immunotherapy.
@ast
Differentiation of naive cord- ...... tation adoptive immunotherapy.
@en
type
label
Differentiation of naive cord- ...... tation adoptive immunotherapy.
@ast
Differentiation of naive cord- ...... tation adoptive immunotherapy.
@en
prefLabel
Differentiation of naive cord- ...... tation adoptive immunotherapy.
@ast
Differentiation of naive cord- ...... tation adoptive immunotherapy.
@en
P2093
P2860
P1433
P1476
Differentiation of naive cord- ...... tation adoptive immunotherapy.
@en
P2093
Daniel Kim
David Smith
George McNamara
Jennifer Bennitt
Joseph Rosenthal
Laurence J N Cooper
Lisa Marie Serrano
Michael C Jensen
Simon Olivares
Stephen J Forman
P2860
P304
P356
10.1182/BLOOD-2005-09-3904
P407
P577
2005-12-13T00:00:00Z